Pioglitazone as Second-Line in Patients With Metastatic Pancreatic Cancer After Treatment With Gemcitabine
Status:
Terminated
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Pioglitazone may slow the growth of tumor cells and may be an effective treatment
for pancreatic cancer.
PURPOSE: This phase I trial is studying how well pioglitazone works as second-line therapy in
treating patients with metastatic pancreatic cancer that progressed after treatment with
gemcitabine.
Phase:
Early Phase 1
Details
Lead Sponsor:
Simmons Cancer Center University of Texas Southwestern Medical Center